The Genotyping Assay Market report also contains a detailed forecast for the years 2019 – 2030. The forecast is aimed at understanding the Genotyping Assay in various ways to assess the share, size and the growth rate of the overall Market worldwide.
Get Your PDF Sample Copy @ https://www.marketindustryreports.com/pdf/7
Technological advancement in PCR to boost the market growth
Polymerase Chain Reaction or PCR is the key technology used by the professionals and researchers for rapid and accurate detection of genetic changes. The introduction of newer technologies in combination with computer programs and database, such as inverse PCR, reverse transcription PCR, assembly PCR and Quantitative PCR (Q-PCR) is expected to fuel the growth of the market. Developments in the sequencing technologies have transformed the sequencing methods into a multifaceted, adaptable molecular tool. Moreover, introduction of automated models in sequencing and high-throughput platforms offer potential growth opportunities in clinical molecular modeling studies, new, gene profiling, chemical entity interactions and genome sequencing.
Increasing number of genetic disorders to propel the market growth
The global genotyping assay market is propelled by a number of factors. One among them is the increase in the number of genetic diseases all around the world. Following that is the general awareness regarding personalized medicine all around the world especially in the developed regions of the world. According to the Parkinson’s Foundation, more than 60 thousand people are diagnosed with the major genetic disorder, Parkinson’s disease in the U.S. every year. Moreover, the number is expected to reach 1 million by 2020
Stringent regulatory policies to affect the small market players
According to the new guidelines by FDA for gene sequencing the testing guidelines and standard are regulated by the three agencies consists of Centers for Medicare and Medicaid Services (CMS), the Federal Trade Commission and the FDA. Furthermore, the stringent regulations harm clinical innovation and also, disproportionally harm small labs and companies that must participate with big companies to submit tests for the FDA approval.
Increasing R&D activities by the major players
Companies are taking R&D initiatives for the developments of innovative products to cater to the growing demands of the population. For instance, Fluidigm Corporation introduced Juno 96.96 Genotyping IFC, a product that analyzes huge number of DNA samples for the Single Nucleotide Polymorphisms (SNPs) in a very short time span.Moreover, genomics service is also provided by RTSF Genomics Core at Michigan State University, that offers genotyping service and technologies.
Key players in the global genotyping assay market are Thermo Fisher Scientific, Illumina, QIAGEN, Agilent Technologies, Danaher Corporation, Roche Diagnostics, GE Healthcare, Fluidigm Corporation, PerkinElmer, Eurofins Scientific, Bio-Rad Laboratories, Pacific Biosciences of California, GENEWIZ, and Integrated DNA Technologies
Read More:
Genotyping Assay Market 2030 Growth by Key Players | GE Healthcare, Agilent Technologies, Qiagen N.V., Eurofins Scientific, Genewiz, Illumina
Aug 20, 2019 (The Expresswire) — Genotyping Assay Market by Product & Services (Reagents & …
Read on marketwatch.com
About Market Industry Reports-
Market Industry Reports is a global leader in market measurement & advisory services, Market Industry Reports is at the forefront of innovation to address the worldwide industry trends and opportunities. We identified the caliber of market dynamics & hence we excel in the areas of innovation and optimization, integrity, curiosity, customer and brand experience, and strategic business intelligence through our research.
Contact Us-
2nd Floor, Manikchand Ikon,
B-Wing, Dhole Patil Road,
Sangamwadi, Pune 411 001
Email: sales@marketindustryreports.com
Phone: + 91 8956 767 535
Website: https://www.marketindustryreports.com/latest-...s?pageno=6
Follow Us- LinkedIn | Twitter Face book
Get Your PDF Sample Copy @ https://www.marketindustryreports.com/pdf/7
Technological advancement in PCR to boost the market growth
Polymerase Chain Reaction or PCR is the key technology used by the professionals and researchers for rapid and accurate detection of genetic changes. The introduction of newer technologies in combination with computer programs and database, such as inverse PCR, reverse transcription PCR, assembly PCR and Quantitative PCR (Q-PCR) is expected to fuel the growth of the market. Developments in the sequencing technologies have transformed the sequencing methods into a multifaceted, adaptable molecular tool. Moreover, introduction of automated models in sequencing and high-throughput platforms offer potential growth opportunities in clinical molecular modeling studies, new, gene profiling, chemical entity interactions and genome sequencing.
Increasing number of genetic disorders to propel the market growth
The global genotyping assay market is propelled by a number of factors. One among them is the increase in the number of genetic diseases all around the world. Following that is the general awareness regarding personalized medicine all around the world especially in the developed regions of the world. According to the Parkinson’s Foundation, more than 60 thousand people are diagnosed with the major genetic disorder, Parkinson’s disease in the U.S. every year. Moreover, the number is expected to reach 1 million by 2020
Stringent regulatory policies to affect the small market players
According to the new guidelines by FDA for gene sequencing the testing guidelines and standard are regulated by the three agencies consists of Centers for Medicare and Medicaid Services (CMS), the Federal Trade Commission and the FDA. Furthermore, the stringent regulations harm clinical innovation and also, disproportionally harm small labs and companies that must participate with big companies to submit tests for the FDA approval.
Increasing R&D activities by the major players
Companies are taking R&D initiatives for the developments of innovative products to cater to the growing demands of the population. For instance, Fluidigm Corporation introduced Juno 96.96 Genotyping IFC, a product that analyzes huge number of DNA samples for the Single Nucleotide Polymorphisms (SNPs) in a very short time span.Moreover, genomics service is also provided by RTSF Genomics Core at Michigan State University, that offers genotyping service and technologies.
Key players in the global genotyping assay market are Thermo Fisher Scientific, Illumina, QIAGEN, Agilent Technologies, Danaher Corporation, Roche Diagnostics, GE Healthcare, Fluidigm Corporation, PerkinElmer, Eurofins Scientific, Bio-Rad Laboratories, Pacific Biosciences of California, GENEWIZ, and Integrated DNA Technologies
Read More:
Genotyping Assay Market 2030 Growth by Key Players | GE Healthcare, Agilent Technologies, Qiagen N.V., Eurofins Scientific, Genewiz, Illumina
Aug 20, 2019 (The Expresswire) — Genotyping Assay Market by Product & Services (Reagents & …
Read on marketwatch.com
About Market Industry Reports-
Market Industry Reports is a global leader in market measurement & advisory services, Market Industry Reports is at the forefront of innovation to address the worldwide industry trends and opportunities. We identified the caliber of market dynamics & hence we excel in the areas of innovation and optimization, integrity, curiosity, customer and brand experience, and strategic business intelligence through our research.
Contact Us-
2nd Floor, Manikchand Ikon,
B-Wing, Dhole Patil Road,
Sangamwadi, Pune 411 001
Email: sales@marketindustryreports.com
Phone: + 91 8956 767 535
Website: https://www.marketindustryreports.com/latest-...s?pageno=6
Follow Us- LinkedIn | Twitter Face book
